Frailty Assessments for Older Patients with Blood Cancers
This observational study is looking at how frailty assessments can help predict outcomes for people aged 60 and older with acute leukemia or myelodysplastic syndromes (MDS). Researchers want to see if these assessments can tell how well patients will do after treatments like chemotherapy (e.g., "7+3," Vyxeos, clofarabine), CAR T-cell therapy (a type of immunotherapy), or allogeneic stem cell transplant (BMT). The study aims to understand if being frail, pre-frail, or not frail affects the risk of non-relapse mortality (death not caused by the cancer returning) one month after treatment. The study plans to enroll 20 participants, but its current status is unclear.
- Study design
- This is an observational study, meaning researchers will watch and collect information without assigning specific treatments. It plans to include 20 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary outcome, non-relapse mortality, is measured at 1-month.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Shannon McCurdy, MD · PRINCIPAL_INVESTIGATOR · Abramson Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Non-Relapse Mortality (NRM) in Frail, Pre-Frail, and Non-Frail patients1-month
NRM will be defined as death without evidence of disease progression or relapse.